SK279913B6 - Farmaceutický prostriedok vo forme krému - Google Patents

Farmaceutický prostriedok vo forme krému Download PDF

Info

Publication number: SK279913B6
Authority: SK; Slovakia
Prior art keywords: weight; cream; parts; dihydroxycholecalciferol; component
Prior art date: 1993-09-01

Application number

SK592-95A

Other languages

English (en)

Slovak (sk)

Other versions

SK59295A3 (en

Inventor

Yuji Makino

Hideo Matugi

Yoshiki Suzuki

Original Assignee

Teijin Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-01

Filing date

1994-09-01

Publication date

1999-05-07

1994-09-01 Application filed by Teijin Limited filed Critical Teijin Limited

1995-12-06 Publication of SK59295A3 publication Critical patent/SK59295A3/sk

1999-05-07 Publication of SK279913B6 publication Critical patent/SK279913B6/sk

Links

239000006071 cream Substances 0.000 title claims abstract description 132
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 89
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims abstract description 62
239000007788 liquid Substances 0.000 claims abstract description 54
239000007787 solid Substances 0.000 claims abstract description 52
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 51
239000004094 surface-active agent Substances 0.000 claims abstract description 46
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims abstract description 43
239000012071 phase Substances 0.000 claims abstract description 38
229960000541 cetyl alcohol Drugs 0.000 claims abstract description 31
239000003871 white petrolatum Substances 0.000 claims abstract description 30
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 25
229940032094 squalane Drugs 0.000 claims abstract description 25
201000004681 Psoriasis Diseases 0.000 claims abstract description 17
239000008346 aqueous phase Substances 0.000 claims abstract description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 claims description 40
235000019271 petrolatum Nutrition 0.000 claims description 33
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 4
239000001587 sorbitan monostearate Substances 0.000 claims description 4
235000011076 sorbitan monostearate Nutrition 0.000 claims description 4
229940035048 sorbitan monostearate Drugs 0.000 claims description 4
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 3
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
239000004147 Sorbitan trioleate Substances 0.000 claims description 3
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 3
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 3
229940075507 glyceryl monostearate Drugs 0.000 claims description 3
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
239000001593 sorbitan monooleate Substances 0.000 claims description 3
235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
229940035049 sorbitan monooleate Drugs 0.000 claims description 3
229960005078 sorbitan sesquioleate Drugs 0.000 claims description 3
235000019337 sorbitan trioleate Nutrition 0.000 claims description 3
229960000391 sorbitan trioleate Drugs 0.000 claims description 3
HWLOKRHECPVOFY-KVVVOXFISA-N (z)-octadec-9-enoic acid;prop-1-ene Chemical compound CC=C.CCCCCCCC\C=C/CCCCCCCC(O)=O HWLOKRHECPVOFY-KVVVOXFISA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 83
239000011647 vitamin D3 Substances 0.000 abstract description 8
229940021056 vitamin d3 Drugs 0.000 abstract description 8
239000003921 oil Substances 0.000 description 120
235000019198 oils Nutrition 0.000 description 118
210000003491 skin Anatomy 0.000 description 57
230000000052 comparative effect Effects 0.000 description 51
238000012360 testing method Methods 0.000 description 43
229940012831 stearyl alcohol Drugs 0.000 description 39
230000035515 penetration Effects 0.000 description 30
-1 etc. Substances 0.000 description 29
238000009472 formulation Methods 0.000 description 27
239000000126 substance Substances 0.000 description 26
229940057995 liquid paraffin Drugs 0.000 description 24
239000004480 active ingredient Substances 0.000 description 22
229920003171 Poly (ethylene oxide) Polymers 0.000 description 21
BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
150000001298 alcohols Chemical class 0.000 description 18
230000000144 pharmacologic effect Effects 0.000 description 17
239000002674 ointment Substances 0.000 description 16
238000010998 test method Methods 0.000 description 14
235000013871 bee wax Nutrition 0.000 description 13
239000012166 beeswax Substances 0.000 description 13
229940092738 beeswax Drugs 0.000 description 13
230000000694 effects Effects 0.000 description 13
239000000839 emulsion Substances 0.000 description 13
238000000034 method Methods 0.000 description 13
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
238000009826 distribution Methods 0.000 description 11
238000010438 heat treatment Methods 0.000 description 11
239000000872 buffer Substances 0.000 description 9
239000003906 humectant Substances 0.000 description 9
239000003755 preservative agent Substances 0.000 description 9
230000002335 preservative effect Effects 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
235000021355 Stearic acid Nutrition 0.000 description 7
239000003963 antioxidant agent Substances 0.000 description 7
230000003078 antioxidant effect Effects 0.000 description 7
235000006708 antioxidants Nutrition 0.000 description 7
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 7
239000004359 castor oil Substances 0.000 description 7
235000019438 castor oil Nutrition 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
239000008117 stearic acid Substances 0.000 description 7
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 7
235000019489 Almond oil Nutrition 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 6
239000008168 almond oil Substances 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
229930195733 hydrocarbon Natural products 0.000 description 6
150000002430 hydrocarbons Chemical class 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000012188 paraffin wax Substances 0.000 description 6
239000008213 purified water Substances 0.000 description 6
235000005282 vitamin D3 Nutrition 0.000 description 6
239000013543 active substance Substances 0.000 description 5
239000000654 additive Substances 0.000 description 5
230000000996 additive effect Effects 0.000 description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
150000004667 medium chain fatty acids Chemical class 0.000 description 5
239000004006 olive oil Substances 0.000 description 5
235000008390 olive oil Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
229960000984 tocofersolan Drugs 0.000 description 5
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 4
239000011627 DL-alpha-tocopherol Substances 0.000 description 4
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
239000004166 Lanolin Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229940039717 lanolin Drugs 0.000 description 4
235000019388 lanolin Nutrition 0.000 description 4
239000007791 liquid phase Substances 0.000 description 4
239000007764 o/w emulsion Substances 0.000 description 4
230000000149 penetrating effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000035807 sensation Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
231100000245 skin permeability Toxicity 0.000 description 4
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 4
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 3
239000004264 Petrolatum Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 3
235000020964 calcitriol Nutrition 0.000 description 3
239000011612 calcitriol Substances 0.000 description 3
229940082500 cetostearyl alcohol Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940031578 diisopropyl adipate Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
229910000403 monosodium phosphate Inorganic materials 0.000 description 3
235000019799 monosodium phosphate Nutrition 0.000 description 3
230000037368 penetrate the skin Effects 0.000 description 3
229940066842 petrolatum Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
239000001993 wax Substances 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
210000001339 epidermal cell Anatomy 0.000 description 2
229960002061 ergocalciferol Drugs 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
239000008299 semisolid dosage form Substances 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000009987 spinning Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
235000001892 vitamin D2 Nutrition 0.000 description 2
239000011653 vitamin D2 Substances 0.000 description 2
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
XOVFABUBLIKHKL-UHFFFAOYSA-N C(C)(=O)ON(CN(OC(C)=O)OC(C)=O)OC(C)=O.[Na] Chemical compound C(C)(=O)ON(CN(OC(C)=O)OC(C)=O)OC(C)=O.[Na] XOVFABUBLIKHKL-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
206010037575 Pustular psoriasis Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000004283 Sodium sorbate Substances 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
IZOWPILIWJADEL-UHFFFAOYSA-N anisole;sodium Chemical compound [Na].COC1=CC=CC=C1 IZOWPILIWJADEL-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000306 component Substances 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000008406 cosmetic ingredient Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000010410 dusting Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000004519 grease Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229960001067 hydrocortisone acetate Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000011164 ossification Effects 0.000 description 1
208000005368 osteomalacia Diseases 0.000 description 1
238000010422 painting Methods 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008250 pharmaceutical cream Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940096112 prednisol Drugs 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229940093625 propylene glycol monostearate Drugs 0.000 description 1
238000007670 refining Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000002884 skin cream Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940037001 sodium edetate Drugs 0.000 description 1
LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
235000019250 sodium sorbate Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000005496 tempering Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Detergent Compositions (AREA)

SK592-95A 1993-09-01 1994-09-01 Farmaceutický prostriedok vo forme krému SK279913B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP21726193		1993-09-01
PCT/JP1994/001443 WO1995006482A1 (en)	1993-09-01	1994-09-01	1α,24-(OH)2-VITAMIN D3 EMULSION COMPOSITION

Publications (2)

Publication Number	Publication Date
SK59295A3 SK59295A3 (en)	1995-12-06
SK279913B6 true SK279913B6 (sk)	1999-05-07

Family

ID=16701374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK592-95A SK279913B6 (sk)	1993-09-01	1994-09-01	Farmaceutický prostriedok vo forme krému

Country Status (17)

Country	Link
US (1)	US5612327A (da)
EP (1)	EP0667166B1 (da)
JP (1)	JP3045179B2 (da)
KR (1)	KR100221045B1 (da)
CN (1)	CN1082818C (da)
AT (1)	ATE195431T1 (da)
CA (1)	CA2148109C (da)
CZ (1)	CZ284261B6 (da)
DE (1)	DE69425552T2 (da)
DK (1)	DK0667166T3 (da)
ES (1)	ES2148340T3 (da)
NO (1)	NO312227B1 (da)
PL (1)	PL175492B1 (da)
PT (1)	PT667166E (da)
SG (1)	SG52313A1 (da)
SK (1)	SK279913B6 (da)
WO (1)	WO1995006482A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5763429A (en) *	1993-09-10	1998-06-09	Bone Care International, Inc.	Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) *	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
AU711716B2 (en)	1995-04-21	1999-10-21	Sekisui Kagaku Kogyo Kabushiki Kaisha	External preparations for treating dermatoses
US20040039030A1 (en) *	1996-09-27	2004-02-26	Hoechst Akeengesellschaft	Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
DE19639816A1 (de) *	1996-09-27	1998-04-02	Hoechst Ag	Antimykotische Mittel mit hoher Wirkstofffreisetzung
US20020128240A1 (en) *	1996-12-30	2002-09-12	Bone Care International, Inc.	Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) *	1996-12-30	2003-05-20	Bone Care International, Inc.	Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) *	1997-02-13	2003-07-10	Bone Care International, Inc.	Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) *	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP4046363B2 (ja) *	1998-03-04	2008-02-13	帝人株式会社	活性型ビタミンｄ３乳剤性ローション剤
ES2368824T3 (es) *	1998-03-27	2011-11-22	Oregon Health & Science University	Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US8263580B2 (en) *	1998-09-11	2012-09-11	Stiefel Research Australia Pty Ltd	Vitamin formulation
AU7895601A (en) *	2000-07-18	2002-01-30	Bone Care Int Inc	Stabilized 1alpha-hydroxy vitamin d
JP2005515996A (ja) *	2001-12-03	2005-06-02	ノバセアインコーポレイティッド	活性型ビタミンｄ化合物を含む薬学的組成物
US20050026877A1 (en) *	2002-12-03	2005-02-03	Novacea, Inc.	Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) *	2003-06-11	2005-01-27	Novacea, Inc.	Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) *	2003-06-11	2006-08-24	Cleland Jeffrey L	Pharmaceutical compositions comprising active vitamin D compounds
US7534894B2 (en)	2003-09-25	2009-05-19	Wyeth	Biphenyloxy-acids
US20060003950A1 (en) *	2004-06-30	2006-01-05	Bone Care International, Inc.	Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) *	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
EP2526930B1 (en) *	2005-06-01	2013-12-25	GlaxoSmithKline Intellectual Property Development Limited	Vitamin formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6226223A (ja) *	1985-07-25	1987-02-04	Teijin Ltd	乾癬治療剤
CA1272953A (en) *	1984-10-08	1990-08-21	Yuji Makino	Pharmaceutical composition for external use containing active-type vitamin d.sub.3
JPH0774144B2 (ja) *	1986-03-12	1995-08-09	久光製薬株式会社	尿素を含有する皮膚用組成物
GB9226860D0 (en) *	1992-12-23	1993-02-17	Leo Pharm Prod Ltd	Novel treatment

1994
- 1994-09-01 CA CA002148109A patent/CA2148109C/en not_active Expired - Lifetime
- 1994-09-01 WO PCT/JP1994/001443 patent/WO1995006482A1/ja not_active Ceased
- 1994-09-01 PL PL94308748A patent/PL175492B1/pl unknown
- 1994-09-01 KR KR1019950701720A patent/KR100221045B1/ko not_active Expired - Lifetime
- 1994-09-01 CZ CZ951132A patent/CZ284261B6/cs not_active IP Right Cessation
- 1994-09-01 EP EP94925612A patent/EP0667166B1/en not_active Expired - Lifetime
- 1994-09-01 JP JP7508038A patent/JP3045179B2/ja not_active Expired - Lifetime
- 1994-09-01 DE DE69425552T patent/DE69425552T2/de not_active Expired - Lifetime
- 1994-09-01 US US08/428,106 patent/US5612327A/en not_active Expired - Lifetime
- 1994-09-01 DK DK94925612T patent/DK0667166T3/da active
- 1994-09-01 PT PT94925612T patent/PT667166E/pt unknown
- 1994-09-01 AT AT94925612T patent/ATE195431T1/de active
- 1994-09-01 SK SK592-95A patent/SK279913B6/sk not_active IP Right Cessation
- 1994-09-01 CN CN94190728A patent/CN1082818C/zh not_active Expired - Lifetime
- 1994-09-01 ES ES94925612T patent/ES2148340T3/es not_active Expired - Lifetime
- 1994-09-01 SG SG1996002669A patent/SG52313A1/en unknown
1995
- 1995-04-28 NO NO19951639A patent/NO312227B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100221045B1 (ko)	1999-09-15
CN1082818C (zh)	2002-04-17
EP0667166B1 (en)	2000-08-16
KR950703998A (ko)	1995-11-17
EP0667166A4 (en)	1995-11-02
WO1995006482A1 (en)	1995-03-09
DE69425552T2 (de)	2001-04-19
CZ284261B6 (cs)	1998-10-14
CA2148109C (en)	1999-11-23
PL308748A1 (en)	1995-08-21
NO951639D0 (no)	1995-04-28
ATE195431T1 (de)	2000-09-15
CA2148109A1 (en)	1995-03-09
NO951639L (no)	1995-06-30
ES2148340T3 (es)	2000-10-16
JP3045179B2 (ja)	2000-05-29
US5612327A (en)	1997-03-18
SG52313A1 (en)	1998-09-28
DK0667166T3 (da)	2000-10-16
CN1114824A (zh)	1996-01-10
DE69425552D1 (de)	2000-09-21
NO312227B1 (no)	2002-04-15
SK59295A3 (en)	1995-12-06
PT667166E (pt)	2001-02-28
PL175492B1 (pl)	1999-01-29
CZ113295A3 (en)	1995-11-15
EP0667166A1 (en)	1995-08-16

Legal Events

Date	Code	Title	Description
2014-11-04	MK4A	Patent expired	Expiry date: 20140901

Publication	Publication Date	Title
SK279913B6 (sk)	1999-05-07	Farmaceutický prostriedok vo forme krému
EP0979654B1 (en)	2005-08-24	Activated vitamin d 3 emulsion-type lotions
JPWO1999044617A1 (ja)	2000-12-19	活性型ビタミンｄ▲下３▼乳剤性ローション剤
EP0981330B1 (en)	2002-08-07	Topical compositions
US4794106A (en)	1988-12-27	Cream
DE3212053A1 (de)	1982-10-21	Kutanapplizierbare pharmazeutische zusammensetzungen
JPWO1995006482A1 (ja)	1995-10-05	１α，２４−（ＯＨ）↓２−Ｖ．Ｄ↓３乳剤性組成物
EP0124147B1 (en)	1987-10-07	Spironolactone containing composition for combating acne
EP0097374A2 (en)	1984-01-04	Corticosteroid topical preparation
CA2312731A1 (en)	1999-06-17	Creams containing vitamin d3 derivatives
HUE027718T2 (en)	2016-10-28	Oil-in-water emulsion containing mometasone and propylene glycol
US20230390196A1 (en)	2023-12-07	Emulsion composition for external use
HU218585B (hu)	2000-10-28	1-alfa,24-(OH)2-V.D3-at tartalmazó emulzió psoriasis kezelésére
CA2156396A1 (en)	1995-06-29	Stable dermatologic preparation containing mycophenolic acid
HUE030827T2 (en)	2017-06-28	Mometasone oil-in-water emulsion